Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
Public ClinicalTrials.gov record NCT04218084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.
Study identification
- NCT ID
- NCT04218084
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 236 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years to 14 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 11, 2020 (Actual)
- Primary completion
- Jan 18, 2024 (Actual)
- Completion
- Nov 6, 2024 (Actual)
- Last update posted
- Mar 10, 2026
2020 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Children's Healthcare of Atlanta: Hughes Spalding | Atlanta | Georgia | 30303 | — |
| Boston Children's Hospital - Clinical Research Pharmacy | Boston | Massachusetts | 02115 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Medical University of South Carolina: Investigational Drug Services | Charleston | South Carolina | 29425 | — |
| Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital | Charleston | South Carolina | 29425 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Texas Children's Hospital - Investigational Pharmacy | Houston | Texas | 77030 | — |
| Texas Children's Hospital- Wallace Tower | Houston | Texas | 77030 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04218084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04218084 live on ClinicalTrials.gov.